Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma Phase II Trials Protocol 4: Vinorelbine

NCT00003259 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00003259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma Phase II Trials Protocol 4: Vinorelbine
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
October 31, 1997
Completion date
September 30, 1999
Enrollment
40 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer